PatientsVille.com Logo

Severe Headache and Bp elite(tm)

PatientsVille

Severe Headache Symptoms and Causes

Encephalitis is an inflammation of the brain. Usually the cause is a viral infection, but bacteria can also cause it. It can be mild or severe. Most cases are mild. You may have flu-like symptoms. With a mild case, you may just need rest, plenty of fluids, and a pain reliever.

Severe cases need immediate treatment. Symptoms of severe cases include

  • Severe headache
  • Sudden fever
  • Drowsiness
  • Vomiting
  • Confusion
  • Seizures

In babies, additional symptoms may include constant crying, poor feeding, body stiffness, and bulging in the soft spots of the skull.

Severe cases may require a stay in the hospital. Treatments include oral and intravenous (IV) medicines to reduce inflammation and treat infection. Patients with breathing difficulties may need artificial respiration. Some people may need physical, speech, and occupational therapy once the illness is under control.

NIH: National Institute of Neurological Disorders and Stroke

Check out the latest treatments for Severe Headache

Severe Headache treatment research studies

Bp elite(tm) clinical trials, surveys and public health registries


Find Drug Side Effect reports



Bp elite(tm) Side Effects


➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Severe Headache Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting Occipital Nerve Stimulation (ONS) for Migraine: OPTIMISE
Condition: Migraine Disorders
Intervention: Device: Occipital nerve stimulator
Outcome Measures: Change in the number of moderate-to-Severe Headache days per month;   Moderate-to-severe headache frequency response;   Conversion to <15 moderate-to-Severe Headache days per month;   Change in average number of moderate-to-Severe Headache hours per day;   Change in daily headache intensity;   Headache intensity response (30%);   Change in headache impact;   Change in migraine-specific quality of life;   Subject satisfaction with treatment;   Rate of adverse events (AEs)
2 Recruiting Pulsed Radiofrequency vs. Steroid Injections for Occipital Neuralgia
Condition: Occipital Neuralgia
Interventions: Procedure: Pulsed radiofrequency;   Drug: Corticosteroid injection
Outcome Measures: Average pain score;   Number of headache days with severe headache;   Depression;   Disability;   Number of days with severe headache
3 Recruiting Impact of a Nurse for Migraine Management: the IMPACT Project
Conditions: Migraine Without Aura;   Migraine With Aura;   Chronic Migraine
Intervention:
Outcome Measures: Hit-6 score change;   Frequency of moderate and severe headache days;   Frequency of headache days;   Chronic headache status;   Medication overuse;   Acute medication intake;   Efficacy of acute treatment;   Response rate to prophylactics;   Short Form 12 score;   Visits to the emergency department;   Severe adverse effects from treatments;   Phone calls returned;   Patient satisfaction;   Phone call return delay;   Global improvement
4 Unknown  Galantamine in the Treatment of Post-Traumatic Headache
Conditions: Post-Traumatic Headache;   Head Trauma,Closed;   Retention Disorders,Cognitive
Intervention: Drug: Galantamine
Outcome Measures: Primary Headache Efficacy Measure; number of pain free days after 3 months;   Consumption of rescue medication;   Number of days with moderate or Severe Headache after 3 months.
5 Recruiting A Study Using Botulinum Toxin Type A as Headache Prophylaxis in Adolescents With Chronic Migraine
Condition: Migraine Disorders
Interventions: Biological: Botulinum toxin type A Dose 1;   Biological: Botulinum toxin type A Dose 2;   Drug: Placebo (Normal Saline)
Outcome Measures: Change from baseline in the frequency of headache days;   Change from baseline in the frequency of Severe Headache days;   Change from baseline in the total cumulative hours of headache on headache days;   Percentage of patients with ≥ 50% decrease from baseline in the frequency of headache days;   Percentage of patients who are prescribed oral rescue migraine prophylactic treatment
6 Recruiting A Study of LY2951742 in Participants With Migraine Headache
Condition: Migraine Headache
Interventions: Drug: LY2951742;   Drug: Placebo
Outcome Measures: Mean Change from Baseline in the Number of Migraine Headache Days in the Last 28-Day Period of the 12-Week Treatment Phase;   Mean Change from Baseline in Number of Migraine Attacks in the Last 28-Day Period of the 12-Week Treatment Phase;   Proportion of Participants With ≥50% Reduction in Number of Migraine Headache Days in the Last 28-Day Period of the 12-Week Treatment Phase;   Mean Change from Baseline in the Number of Days of Medication Use for the Treatment of Migraine Headache in the Last 28-Day Period of the 12-Week Treatment Phase;   Mean Change from Baseline in Number of Headache Hours in the Last 28-Day Period of the 12-Week Treatment Phase;   Change from Baseline to 12 Week Endpoint in Migraine Specific Quality of Life (MSQL) Questionnaire Scores;   Change from Baseline to 12 Week Endpoint in the Headache Impact Test-6™ (HIT-6™) Scores;   Serum Concentration of LY2951742;   Plasma Concentration of Calcitonin Gene-Related Peptide (CGRP);   Percentage of Participants Developing Anti-drug Antibodies to LY2951742;   Percentage of Participants with Suicidal Ideation and Behaviors Assessed by the Columbia Suicide Severity Rating Scale (C-SSRS) Scores;   Mean Change from Baseline in the Number of Headache Days in the Last 28-Day Period of the 12-Week Treatment Phase;   Mean Change from Baseline in the Number of Moderate-Severe Headache Days in the Last 28-Day Period of the 12-Week Treatment Phase
7 Recruiting Sumatriptan as Treatment for Post-traumatic Headache
Condition: Post-traumatic Headache
Intervention: Drug: Sumatriptan 100 mg
Outcome Measures: Headache relief;   Adverse events;   Compliance
8 Unknown  Prazosin Vibrostimulation Autonomic Dysreflexia and Spinal Cord Injury Study
Condition: Autonomic Dysreflexia
Intervention: Drug: Prazosin HCL
Outcome Measures: The hypothesis will be tested by measuring three parameters during prazosin and non-prazosin trials in which ejaculation occurs.;   Objective parameters: absolute beat-to-beat BP, differences between systolic and diastolic BP readings, heart rate variability, heart rate and ECG readings (looking for irregular rhythms) and visible signs of AD experienced by the subject;   Subjective parameters: subject perceived efficacy and side effects of the medication and willingness to use the medication at home;   Secondary outcomes will include the subject's knowledge of AD.
9 Recruiting Comparing Carotid Stenting With Endarterectomy in Severe Asymptomatic Carotid Stenosis
Condition: Carotid Stenosis
Interventions: Procedure: carotid artery stenting;   Procedure: carotid endarterectomy
Outcome Measures: comparison of cardiovascular mortality and morbidity which includes cardiac and neurological morbidity (TIA and CVA) in the two invasive treatments of asymptomatic carotid artery stenosis;   incision site morbidity;   cranial nerves damage;   brain hyperperfusion;   bradycardia within the first 24 hours;   microembolic brain events;   long term recurrence;   effect on patient life style
10 Recruiting Study of Rizatriptan in the Treatment of Acute Attacks of Post-traumatic Headache in U.S. Military Troops
Condition: Chronic Post-traumatic Headache
Interventions: Drug: Rizatriptan;   Drug: Placebo
Outcome Measures: Headache Severity;   24 hour Migraine Quality of Life score
11 Unknown  A Pilot Study of Demand Valve Oxygen Inhalation Therapy for Cluster Headache
Condition: Cluster Headache
Intervention: Drug: Oxygen
Outcome Measures: Reduction in headache pain;   Headache relief and pain free
12 Recruiting Chordate System S020 Acute Migraine Clinical Investigation
Condition: Acute Migraine
Interventions: Device: Chordate System S020 in treatment mode;   Device: Chordate System S020 in placebo mode
Outcome Measures: Headache relief;   Pain-free rate;   Incidence of recurrence;   24 hour sustained pain-free rate;   48 hour sustained pain-free rate;   Time to meaningful relief;   Change in nausea, photophobia, phonophobia, vomiting and disability;   Subject global impression;   Use of rescue medication;   Frequency, severity, device-relationship and outcome of all adverse events
13 Recruiting Alteration in Hearing Following Accidental Dural Puncture. A Study in Parturients
Condition: Parturients in Labour
Intervention:
Outcome Measures: Post-dural puncture headache;   Audiometric data;   PDPH questionnaire;   Recurrence of Headache
14 Not yet recruiting Botox Injection in Treatment of Chronic Migraine
Condition: Migraine Disorders
Intervention: Drug: Botulinum Toxin Type A
Outcome Measures: Number of adverse events and number of participants with adverse events;   Days with migraine for week 4, 8 and 12;   Days with moderate or severe migraine per 4 weeks;   Migraine attack frequency (number of migraine attacks per 4 weeks);   Days without migraine;   Hours with migraine per 4 weeks;   Duration of migraine attack
15 Unknown  NSAID RCT for Prevention of Altitude Sickness
Condition: Spectrum of Altitude-associated Neurologic Forms of Altitude
Intervention: Drug: Ibuprofen 600mg orally three times daily
Outcome Measures: Change in the incidence of AMS as measured on the Lake Louise AMS Questionnaire across the study.;   1. Change in High Altitude Headache measured by the Visual Analog Scale (VAS) across the study.;   2. Change in cognitive performance as measured by King-Devick across the study.;   3. Change in the presence of anxiety and somatic symptoms using the BSI-12 screening tool across the study;   4. Change in the oxygen concentration using Pulse Oximetry across the study.;   5. Change in hydration status as measured by urine specific gravity across the study.;   6. Change in HAH incidence and severity as measured on the Lake Louise AMS Questionnaire across the study.;   7. Change in cognitive performance as measured by the Quickstick across the study;   8. Change in the presence of anxiety and somatic symptoms using the GAD-2 screening tool across the study;   9. Incidence of severe AMS as measured by a score of 6 or greater on the Lake Louise AMS Questionnaire.
16 Recruiting Study to Determine the Efficacy and Safety of ELS-M11 in Acute Migraine
Condition: Migraine Headaches
Interventions: Drug: ELS-M11;   Drug: Placebo
Outcome Measures: Percentage of patients who experience pain relief 2 hours following the first application of ELS-M11;   Percentage of patients who report pain relief at various time points within a 24 hour period, following the first application of ELS-M11;   Percentage of patients who report complete pain resolution within 24 hours following the first application of ELS-M11.;   Percentage of patients who report sustained pain relief after the first application of ELS-M11;   Percentage of patients who report sustained complete pain resolution after the first application of ELS-M11.;   Time to Initial Use of Rescue Medication following the first application of ELS-M11;   Use of Rescue Medication following the first application of ELS-M11 by 24 hours;   Resolution of migraine-associated symptoms, following the first application of ELS-M11;   Percentage of patients who can resume or maintain their normal routine, following the first application of ELS-M11.
17 Unknown  Randomized Evaluation of Octreotide Versus Compazine for Emergency Department Treatment of Migraine Headache
Condition: Migraine Headache
Intervention: Drug: Octreotide
Outcome Measures: Patient Satisfaction;   Improvement of Pain;   Improvement of Nausea
18 Recruiting İs There a Relationship Between Severity of Preeclampsia and Maternal Heavy Metal Levels?
Conditions: Mild Pre-eclampsia;   Severe Preeclampsia
Intervention:
Outcome Measure: increased levels of heavy metals in preeclamptic women
19 Recruiting Treatment and Natural History Study of Lymphomatoid Granulomatosis
Conditions: Lymphomatoid Granulomatosis;   Granulomatosis, Lymphomatoid;   Non-Hodgkins Lymphoma;   Lymphoproliferative Disorder
Interventions: Biological: Interferon;   Drug: Rituxan and EPOCH
Outcome Measure: Overall response and long-term efficacy
20 Recruiting Genetic Analysis of Children With Cyclic Vomiting Syndrome (CVS) and Migraines
Conditions: Vomiting Syndrome;   Migraines
Intervention:
Outcome Measures: Identify novel genes that contribute to the risk of CVS using genomewide association analysis approach.;   Perform genotype-phenotype correlations between genetic profiles and various phenotypes of CVS (e.g. menstrual, Sato, calendar-tied) and migraine headaches (e.g. with aura, without aura, hemiplegic migraine)